Company Number: 14062545

Analysis Date: 2025-07-19 11:51 UTC

1. Credit Opinion: DECLINE
   Zeus Sleep Ltd is a very early-stage business incorporated in 2022, showing minimal financial activity and no meaningful trading history. The latest accounts report negligible assets (£10) and shareholders’ funds (£10), with no income statement or profit figures available. There is no evidence of revenue generation or cash inflows to support debt servicing. The company’s financial position is extremely weak, lacking tangible assets or working capital, which raises significant concerns about its ability to meet loan repayments or commercial obligations. Given the absence of financial substance and operating performance, credit approval is not recommended at this time.

2. Financial Strength:
   The balance sheet is minimal with current assets (debtors) of £10 and no reported liabilities beyond this level. Share capital is nominal (£16.76 issued, £10 called-up in the accounts). The company’s net assets and shareholders’ funds stand at £10 consistently over the past three years, indicating no financial growth or accumulation of earnings. The lack of fixed assets or cash reserves highlights a very fragile financial base. This suggests the company is either pre-trading or in a development phase without commercial traction.

3. Cash Flow Assessment:
   No cash or cash equivalents are disclosed in the accounts, and debtors are negligible at £10. There is no indication of operating cash flow or working capital beyond this nominal amount. Without evidence of sales, receipts, or other income, liquidity is critically insufficient to cover any operating expenses or debt servicing. The company’s ability to maintain positive cash flow is highly uncertain, increasing the risk of default.

4. Monitoring Points:

• Monitor the filing of full accounts including the profit and loss statement in the next reporting cycle to assess trading performance.
• Track any material changes in current assets or liabilities indicating operational progress or capital injection.
• Review any new debt facilities applied for and the company’s ability to meet repayment terms.
• Observe changes in management or PSC that might influence financial strategy or risk profile.